Found: 8
Select item for more details and to access through your institution.
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3165, doi. 10.1007/s13555-023-01059-y
- By:
- Publication type:
- Article
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1777, doi. 10.1007/s13555-021-00598-6
- By:
- Publication type:
- Article
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 3, p. 203, doi. 10.1002/cpdd.139
- By:
- Publication type:
- Article
Circulating tumor cells in breast cancer: a tool whose time has come of age.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Circulating tumor cells in breast cancer: A tool whose time has come of age.
- Published in:
- BMC Medicine, 2011, v. 9, n. 1, p. 43, doi. 10.1186/1741-7015-9-43
- By:
- Publication type:
- Article
Circulating tumor cells in breast cancer: A tool whose time has come of age.
- Published in:
- BMC Medicine, 2011, v. 9, n. 1, p. 43, doi. 10.1186/1741-7015-9-43
- By:
- Publication type:
- Article
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
- Published in:
- BMC Cancer, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11316-0
- By:
- Publication type:
- Article